학술논문
Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series
Document Type
article
Source
Clinical Case Reports, Vol 8, Iss 12, Pp 3142-3147 (2020)
Subject
Language
English
ISSN
2050-0904
Abstract
Key Clinical Message The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID‐19. Serum ferritin levels and lymphocytopenia are promising markers for disease severity and disease progression that are commonly available in general clinical practice.